|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
173,744,000 |
Market
Cap: |
785.32(M) |
Last
Volume: |
148,509 |
Avg
Vol: |
0 |
52
Week Range: |
$3.98 - $15.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
17,604 |
53,676 |
Total Buy Value |
$0 |
$0 |
$160,420 |
$460,539 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
3 |
Total Shares Sold |
13,017 |
239,658 |
533,787 |
1,021,534 |
Total Sell Value |
$55,583 |
$1,515,468 |
$5,939,550 |
$11,424,036 |
Total People Sold |
2 |
7 |
8 |
10 |
Total Sell Transactions |
2 |
9 |
16 |
43 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mccourt Thomas A |
Chief Commercial Officer |
|
2017-02-22 |
4 |
AS |
$16.94 |
$25,749 |
D/D |
(1,520) |
28,050 |
|
- |
|
Graney Thomas |
Chief Financial Officer |
|
2017-02-22 |
4 |
AS |
$16.94 |
$31,746 |
D/D |
(1,874) |
20,763 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2017-02-22 |
4 |
AS |
$16.94 |
$30,492 |
D/D |
(1,800) |
21,258 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2017-02-14 |
4 |
AS |
$16.75 |
$626,199 |
D/D |
(37,385) |
0 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2017-02-14 |
4 |
OE |
$3.76 |
$140,568 |
D/D |
37,385 |
37,385 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2017-01-18 |
4 |
OE |
$2.94 |
$164,602 |
D/D |
55,987 |
775,000 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2017-01-12 |
4 |
AS |
$15.50 |
$511,407 |
D/D |
(32,994) |
4,670,322 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2017-01-12 |
4 |
OE |
$2.94 |
$97,002 |
D/D |
32,994 |
4,703,316 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2017-01-11 |
4 |
AS |
$15.84 |
$522,609 |
D/D |
(32,993) |
4,670,322 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2017-01-11 |
4 |
OE |
$2.94 |
$96,999 |
D/D |
32,993 |
4,703,315 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2017-01-06 |
4 |
OE |
$2.94 |
$99,998 |
D/D |
34,013 |
719,013 |
|
- |
|
Schulman Amy W |
Director |
|
2017-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,793 |
9,793 |
|
- |
|
Consylman Gina |
Chief Accounting Officer |
|
2016-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
31,623 |
|
- |
|
Walsh Christopher T Phd |
Director |
|
2016-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
161 |
71,357 |
|
- |
|
Mcguire Terrance |
Director |
|
2016-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
161 |
44,414 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2016-12-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,500 |
23,058 |
|
- |
|
Olanoff Lawrence S |
Director |
|
2016-12-05 |
4 |
AS |
$15.68 |
$50,176 |
D/D |
(3,200) |
26,105 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2016-11-11 |
4 |
AS |
$16.75 |
$234,500 |
D/D |
(14,000) |
0 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2016-11-11 |
4 |
OE |
$3.76 |
$52,640 |
D/D |
14,000 |
14,000 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2016-10-31 |
4 |
OE |
$2.94 |
$882,000 |
D/D |
300,000 |
685,000 |
|
- |
|
Walsh Christopher T Phd |
Director |
|
2016-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
71,196 |
|
- |
|
Mcguire Terrance |
Director |
|
2016-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
44,253 |
|
- |
|
Olanoff Lawrence S |
Director |
|
2016-09-06 |
4 |
AS |
$13.72 |
$43,904 |
D/D |
(3,200) |
29,305 |
|
- |
|
Consylman Gina |
Chief Accounting Officer |
|
2016-08-19 |
4 |
AS |
$13.54 |
$2,803 |
D/D |
(207) |
21,123 |
|
- |
|
Walsh Christopher T Phd |
Director |
|
2016-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
196 |
71,030 |
|
- |
|
589 Records found
|
|
Page 18 of 24 |
|
|